EP1926709A1 - Verfahren zur herstellung einer chiralen 3-hydroxypyrrolidinverbindung und derivaten davon mit hoher optischer reinheit - Google Patents

Verfahren zur herstellung einer chiralen 3-hydroxypyrrolidinverbindung und derivaten davon mit hoher optischer reinheit

Info

Publication number
EP1926709A1
EP1926709A1 EP06783728A EP06783728A EP1926709A1 EP 1926709 A1 EP1926709 A1 EP 1926709A1 EP 06783728 A EP06783728 A EP 06783728A EP 06783728 A EP06783728 A EP 06783728A EP 1926709 A1 EP1926709 A1 EP 1926709A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
chiral
group
compound
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06783728A
Other languages
English (en)
French (fr)
Other versions
EP1926709A4 (de
Inventor
Chung-Woo Lim
Chang Jin Boo
Ki Hyun Kim
Seong-Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RStech Corp
Original Assignee
RStech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RStech Corp filed Critical RStech Corp
Priority claimed from KR1020060080184A external-priority patent/KR100743617B1/ko
Publication of EP1926709A1 publication Critical patent/EP1926709A1/de
Publication of EP1926709A4 publication Critical patent/EP1926709A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for the preparation of a chiral
  • the present invention relates to an efficient process for the preparation of optically pure chiral 3-hydroxypyrrolidine compound and derivatives thereof, comprised of introducing a suitable protecting group to the starting material 3-chloro-2-hydroxypropionitrile in order to prevent formation of side products during reduction of the nitrile group of the starting material and in-situ intramolecular cyclization at a hydrogenation reaction.
  • Chiral 3-hydroxypyrrolidine and derivatives thereof are essential intermediates of a variety of chiral medicines, including antibiotics, analgesics, thrombolytic drugs, antipsychotics, etc.
  • Various drugs derived from 3-hydroxypyrrolidine and derivatives thereof are commercially available.
  • Several compounds are also reported to be clinically tested. Therefore, it is expected that the demand on chiral 3-hydroxypyrrolidine and its derivatives increases more and more. For these reasons, researches on the inexpensive and efficient production of chiral 3-hydroxypyrrolidine and derivatives thereof take an important role in the field of medicine industry.
  • chiral 3-hydroxypyrrolidine derivative was also prepared from decarbonation of chiral 4-hydroxy-2-pyrrolidinecarboxylic acid through combinational treatment with 2-cyclohexen-l-one and cyclohexanol [WO 91/09013; U.S. Patent No. 5,233,053; Chem. Lett., 1986, 893].
  • this process is complicated and exhibits a low yield, making it inappropriate for industrial- scale production.
  • the method according to the present invention is a safe process and applicable to mass production of the optically pure chiral 3-hydroxypyrrolidine compound.
  • 3-hydroxypyrrolidine compound represented by formula 1 is prepared from the following reactions: protection of the hydroxy group of the chiral 3-chloro-2-hydroxypropionitrile represented by formula 2, hydrogenation of the obtained product, optional N-derivatization, and deprotection.
  • the protection of the hydroxyl group of the chiral 3-chloro-2-hydroxypropionitrile can minimize side reactions during the hydrogenation and increases the total yield.
  • the targeted compound is prepared in high optical purity. Further, the protection of the hydroxyl group effectively prevents the competitive derivatization by the oxygen atom of the hydroxyl group.
  • the intermediate compounds from the chiral 3-chloro-2-hydroxypropionitrile can be subject as a crude product, without any particular purification, to the subsequent reactions such as hydroxy protection, hydrogenation, optional derivatization and deprotection, This simplifies the reaction process and improves the production yield. Accordingly, the process of the present invention makes it possible to produce the 3-hydroxypyrrolidine compound represented by formula 1, which is an essential intermediate for a variety of chiral medicines, in an effective manner and in an industrial scale. Best Mode for Carrying Out the Invention
  • the present invention relates to an effective process for the preparation of a chiral
  • the process in accordance with the present invention comprises the steps of (a) protecting a hydroxy group of chiral 3-chloro-2-hydroxypropionitrile with a hydroxy-protecting group, (b) subjecting the obtained hydroxy-protected compound to a hydrogenation reaction to obtain a corresponding hydroxy-protected pyrrolidine compound or hydrochloride salt thereof and (c) if necessary, deprotecting the hydroxy-protected pyrrolidine compound, or N - derivatizing the hydroxy-protected pyrrolidine compound by reacting the hydroxy- protected pyrrolidine compound with a substrate susceptible to a nucleophilic attack and then deprotecting the obtained N-derivatized pyrrolidine compound.
  • the process in accordance with the present invention is summarized in the following scheme 1 :
  • the chiral 3-chloro-2-hydroxypropionitrile represented by formula 2 is used as starting material in the present invention.
  • the starting material is easily obtainable from nucleophilic ring opening of chiral epichlorohydrin.
  • Korean Patent No. 491809 and references cited therein please refer to Korean Patent No. 491809 and references cited therein.
  • the chiral 3-chloro-2-hydroxypropionitrile can be effectively prepared from the reaction of commercially available chiral epichlorohydrin with sodium cyanide in a presence of citric acid.
  • the targeted chiral 3-hydroxypyrrolidine compound can be prepared in high yield and with high optical purity, through subsequent reactions: protection of the hydroxy group; reduction of the nitrile group and in situ intramolecular cyclization by hydrogenation; optional JV-derivatization and/or de- protection of the hydroxyl protecting group.
  • the reduction of the nitrile group is one of effective organic synthesis techniques to prepare a primary amine and is a commercially available process [The Chemistry of the Cyano Group, John Wiley and Sons, 1970, Chapter 7; U.S. Patent No. 5,237,088; U.S. Patent No. 5,801,286; U.S. Patent No. 5,777,166].
  • the reduction of the nitrile group were carried out in a presence of various reducing agents, for example, metal hydrides such as lithium aluminum hydride or sodium borohydride, optionally in combination with an additive [Chem. Soc.
  • the primary amine compound can be prepared by reducing the nitrile group through hydrogenation in a presence of a metal catalyst such as palladium, platinum, Raney nickel, Raney cobalt, etc. This process is advantageous in that the product can be easily obtained by filtering out the catalyst and removing the solvent.
  • a metal catalyst such as palladium, platinum, Raney nickel, Raney cobalt, etc.
  • 3-hydroxypyrrolidine could not be obtainable in high yield and with high purity from direct hydrogenation of the chiral 3-chloro-2-hydroxypropionitrile of formula 2 due to the formation of various side products. Moreover, since the side reactions were reinforced in a large-scale preparation, new solution to avoid the problems should be investigated.
  • the starting material chiral S-chloro ⁇ -hydroxypropionitrile
  • a hydroxy-protecting group it is crucial that the hydroxy-protecting group should not be decomposed during the subsequent hydrogenation.
  • the present inventors tried to protect the hydroxy group of the compound of formula 2 with acyl compounds such as acetyl or benzoyl compound, prior to the hydrogenation.
  • these hydroxy-protecting groups were found to be insufficient because they were deprotected under high pressure condition of the hydrogenation.
  • the production yield of hydrogenation and subsequent deprotection in a situation that an alkyl group such as methyl or tetrahydropyran was introduced, as a protecting group, to protect the hydroxy group of the compound the formula 2, was found to be as low as 30 %.
  • hydroxy-protecting group is a silyl group.
  • the chiral 3-chloro-2-hydroxypropionitrile having formula 2 is firstly reacted with a silylizing agent to accomplish the protection of the hydroxy group of the chiral 3-chloro-2-hydroxypropionitrile with a silyl group.
  • a silylizing agent is firstly reacted with a silylizing agent to accomplish the protection of the hydroxy group of the chiral 3-chloro-2-hydroxypropionitrile with a silyl group.
  • R', R" and R'" represent substituents.
  • R', R" and R'" are, each independently, C -C alkyl, C -C cycloalkyl, C -C alkene, C -C alkyne, C -C alkoxy, C -C aryl or (CH ) -R (wherein R is C -C cycloalkyl, C -C alkene, C -C alkyne, C
  • the silyl group, introduced as a hydroxyl protecting group, is very stable under various chemical reaction conditions, excluding an acidic condition.
  • the introduction and deprotection of the silyl group can be easily carried out [Protecting Groups, Thieme Medical Publishers Inc,. New York, 1994; Protective Groups in Organic Synthesis, John Wiley and Sons, Inc, 1991].
  • the protection of the hydroxy group with the silyl group can be easily achieved by reacting a chiral 3-chloro-2-hydroxypropionitrile compound of formula 2 with a silylizing agent in a presence of a base.
  • the silylizing agent that can be represented by R'R"R'"Si-Y (wherein, R', R" and R'" are the same as defined in the above and Y represents a leaving group such as halide or sulfonate) is added in an amount of 0.8 - 5 equivalents, preferably in an amount of 1.0 - 2 equivalents, based on the chiral 3-chloro-2-hydroxypropionitrile of formula 2.
  • a base imidazole, 2,6-lutidine, N,N - dimethylaminopyridine and salts thereof, tertiary amine and hydrates thereof can be mentioned.
  • Preferable is trialkylamine.
  • trialkylamine examples include trimethylamine, triethylamine and diisopropylethylamine.
  • the base is added in an amount of 0.8 - 10 equivalents, preferably in an amount of 1.0 - 3.0 equivalents, based on the chiral 3-chloro-2-hydroxypropionitrile of formula 2.
  • An organic solvent that can be used in the protection reaction is not particularly limited, and any one that is common in the art can be used. Examples of the organic solvent include N, N - dimethylformamide, aliphatic or aromatic hydrocarbon, halogenated hydrocarbon and ethers.
  • aromatic organic solvents such as toluene and benzene, halogenated alkane such as dichloromethane and chloroform and ethers such as ethyl ether, tetrahydrofuran and dioxane may be used.
  • Reaction temperature is preferably in the range of 0 to 100 0 C, more preferably of 10 to 4O 0 C.
  • Another preferable hydroxy-protecting group is a benzyl group.
  • the benzyl group is known to be deproteced during the hydrogenation reaction. Nonetheless, the benzyl group, introduced as a hydroxy-protecting group of the chiral 3-chloro-2-hydroxypropionitrile, is stable under the hydrogenation using Raney nickel and provides satisfactory results.
  • a metal catalyst such as palladium and platinum, the benzyl group was deprotected during the hydrogenation and showed very low yield.
  • * represents a chiral center and Z means a hydroxy-protecting group, preferably a silyl group.
  • the nitrile group of the hydroxy-protected compound of formula 3 is firstly reduced through the hydrogenation, providing a primary amine compound.
  • the resultant intermediate represented by the formula 5 undergoes in situ intramolecular cyclization.
  • a hydroxy-protected pyrrolidine compound or hydrochloride salt thereof, which is represented by formula 4 is obtained.
  • the ratio of the free hydroxy-protected pyrrolidine (free base) to the hydrochloride salt thereof depends upon the metal catalyst used in the hydrogenation and pH of the reaction. In any case, the hydroxy-protected pyrrolidine compound can be obtained as a free base by treating with 0.5 - 1 equivalent of a base.
  • the hydrogenation is performed in a presence of a metal catalyst and under hydrogen atmosphere.
  • the metal catalyst that can be used in the hydrogenation is not particularly limited and may be any one generally known in the art. Preferable is palladium (Pd), platinum (Pt), Raney nickel (Raney-Ni) and Raney cobalt (Raney-Co). In a case that the benzyl group is used as the hydroxy-protecting group, Raney nickel (Raney-Ni) is preferable.
  • the metal catalyst is added in an amount of 5 - 80 wt%, preferably in an amount of 5 - 25 wt%.
  • the hydrogen gas is supplied in a pressure of 1 - 50 bar, preferably 2-10 bar.
  • the reaction is performed at a temperature of 25 - 200 0 C, preferably 50 - 15O 0 C under stirring for 1 - 30 hours, preferably 2 - 5 hours. After all the reactants were consumed, typical filtration and distillation under reduced pressure gave a hydroxy-protected pyrrolidine compound or hydrochloride salt thereof, which is represented by formula 4.
  • the solvent to be used is not particularly limited and may be any one commonly used in the art. Specifically, JV,./V-dimethylformamide, dimethyl sulfoxide, aliphatic or aromatic hydrocarbon, halogenated hydrocarbon, ether or alcohol may be used.
  • the alcohol include C 1 -C 4 alcohol, such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol and ?-butanol.
  • C 1 -C 4 alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol and ?-butanol.
  • the meal catalyst is filtered out and the volatile solvent is removed by distillation under reduced pressure to give the hydroxy-protected pyrrolidine represented by the formula 4 or its hydrochloride salt.
  • the obtained crude product can be then directly subject to the next derivatization or deprotection without any further special purification. Since the hydroxy-protected pyrrolidine compound of formula 4 or its hydrochloride salt is prepared in a high purity, the purification process is simplified and the production yield is improved.
  • the hydrochloride salt of the hydroxy-protected pyrrolidine was treated with an inorganic base (e.g., NaOH) to obtain a free base.
  • an inorganic base e.g., NaOH
  • the compound represented by the formula 4 can be directly applicable to the deprotection or the N-derivatization in the form of hydrochloride salt, because deprotection is not affected by the presence of HCl.
  • N-derivatization is affected by the presence of HCl, because the ⁇ -derivatization is normally performed in a presence of excess base.
  • the pyrrolidine compound of formula 4 can be used in the deprotection and the N-derivatization in a form of the hydrochloride salt.
  • the resultant hydroxy-protected pyrrolidine compound or its hydrochloride salt represented by formula 4 is converted to the chiral 3-hydroxypyrrolidine or derivatives thereof through optional N-derivatization and deprotection.
  • the targeted chiral 3-hydroxypyrrolidine or N-substituted chiral 3-hydroxypyrrolidine having formula 1 is prepared from the hydroxy-protected pyrrolidine compound of formula 4 or its hydrochloride salt.
  • Deprotection under the acidic condition gives chiral 3-hydroxypyrrolidine as an acid additive salt, from which the chiral 3-hydroxypyrrolidine can be easily recovered during a workup process by the treatment with a base (e.g., an inorganic base containing hydroxy, phosphate or carbonate group).
  • a base e.g., an inorganic base containing hydroxy, phosphate or carbonate group.
  • Deprotection of the benzyl group is accomplishable through hydrogenation in a presence of a metal catalyst such as palladium and platinum.
  • a metal catalyst such as palladium and platinum.
  • the targeted pyrrolidine compound is a benzyl-protected compound, deprotection would be unnecessary.
  • Specific conditions for the de- protection of the silyl group are as follows.
  • the hydroxy-protected pyrrolidine compound of formula 4 or its hydrochloride salt is firstly dissolved into an organic solvent and a deprotecting agent is added, under stirring, to the solution in an amount of 0.1 - 10 equivalents (preferably in 0.5 - 2.0 equivalents) at a reaction temperature of 0 - 100 0 C (preferably 10 - 3O 0 C).
  • the solvent is not particularly limited and may be anyone commonly used in the art. Specifically, ⁇ f, ⁇ f-dimethylformamide, dimethyl sulfoxide, aliphatic or aromatic hydrocarbon, halogenated hydrocarbon, ether or alcohol may be used.
  • the alcohol include C -C alcohol, such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol and ?-butanol.
  • C -C alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol and ?-butanol.
  • the hydroxy-protected pyrrolidine compound of formula 4 is sequentially subject to JV-derivatization and deprotection to provide chiral JV-substituted 3-hydroxypyrrolidine compound.
  • the JV-derivatization is performed by reacting the hydroxy-protected pyrrolidine compound of formula 4 with a substrate susceptible to a nucleophilic attack. That is, the ./V-derivatization is carried out by nucleophilic attack of the nitrogen atom of the hydroxy-protected pyrrolidine compound of formula 4 to the substrate susceptible to the nucleophilic attack.
  • the substrate susceptible to the nucleophilic attack is typically represented by the formula R-Y (wherein R is car- bohydride and Y is a leaving group).
  • R is car- bohydride and Y is a leaving group.
  • the leaving group include a halogen atom, sulfonate and anhydride.
  • the substrate is normally added in an amount of 0.8 - 2 equivalents, preferably in an amount of 1.0 - 2.0 equivalents.
  • the N - derivatization is performed in a presence of a base.
  • the base include imidazole, 2,6-lutidine, JV,./V-dimethylaminopyridine and salts thereof, tertiary amine and hydrates thereof.
  • Preferable is trialkylamine.
  • trialkylamine examples include trimethylamine, triethylamine and diisopropylethylamine.
  • the base is added in an amount of 0.8 - 10 equivalents, preferably in an amount of 1.0 - 3.0 equivalents, based on the hydroxy-protected pyrrolidine compound of formula 4.
  • the organic solvent used in the reaction is not particularly limited and may be anyone commonly used in the art. Examples of the organic solvent include JV,./V-dimethylformamide, aliphatic or aromatic hydrocarbon, halogenated hydrocarbon and ether.
  • aromatic organic solvents such as toluene and benzene, halogenated alkanes such as dichloromethane and chloroform or ethers such as ethyl ether, tetrahydrofuran and dioxane may be used.
  • Reaction temperature can be suitably adjustable depending on the substrate to be used, which is well known to the person of ordinary skill in the art. Typically, the reaction is carried out at a temperature of 0 - 100 0 C.
  • the targeted compound is obtainable in high purity after typical workup process.
  • the resulting compound can be applicable to the next deprotection without any further special purification (e.g., fractional distillation and recrystallization). This contributes to the simplification of the process and the improvement of production yield.
  • the deprotection process can be carried out in the same manner as described in the above. After de- protection of the hydroxy-protecting group, the targeted chiral JV-substituted 3-hydroxypyrrolidine compound is finally prepared.
  • the chiral 3-hydroxypyrrolidine may directly undergo N - derivatization by the reaction with a substrate susceptible to nucleophilic attack and the obtained compound is used as an intermediate in the synthesis of chiral medicines.
  • direct derivatization of the chiral 3-hydroxypyrrolidine compound involves competitive derivatization by the nitrogen atom and the oxygen atom of the chiral 3-hydroxypyrrolidine.
  • both the nitrogen atom and the oxygen atom competitively participate in the derivatization reaction.
  • the competitive nucleophilic attack by the oxygen atom produces adverse side product, which reduces the production yield of the target compound and makes the purification process complicated.
  • 3-hydroxypyrrolidine compound represented by the following formula 1 can be prepared:
  • Z represents hydrogen or benzyl and R is hydrogen, C -C alkyl
  • C cycloalkyl, C -C cycloalkenyl, heterocycle or polycycle C -C carbonyl, C -C carboxyl, silyl, ether, thioether, selenoether, ketone, aldehyde, ester, phosphoryl, r phos ⁇ phonate, ' X p-hos I p-hine,' sulfony J l or ( y CH 2 ) k -R 3 (wherein R 3 is C 2 -C 10 alkene, C 2 -C 10 alkyne, C -C alkoxy, C -C aryl, C -C cycloalkyl, C -C cycloalkenyl, heterocycle
  • Example 4 (66.9 mmol) obtained from Example 4 was dissolved into methanol (40 mL), 25 wt% of Raney-Ni catalyst suspended in methanol (40 mL) was added. The mixture was stirred under 20 bar of hydrogen pressure while varying the reaction temperatures of 3O 0 C to 12O 0 C.
  • the target compound (/?)-3-(?-butyldimethylsilyloxy)pyrrolidine was obtained in the same manner as described in the Example 5.
  • Example 4 (66.9 mmol) obtained in Example 4 was dissolved into methanol (40 mL), 25 wt% of Raney-Ni catalyst suspended in methanol (40 mL) was added. The mixture was stirred at 5O 0 C, 7O 0 C and 100 0 C, respectively, while varying the hydrogen pressure.
  • the target compound (/?)-3-(?-butyldimethylsilyloxy)pyrrolidine was obtained in the same manner as described in the Example 5.
  • Example 10 Preparation of (R )- N -benzyl-3-hydroxypyrrolidine [91] To 2 L high-pressure reactor, 100 g of (R)-2-(t - butyldimethylsilyloxy)-3-chloropropionitrile dissolved into methanol (500 mL) and 25 g of Raney-Ni suspended in methanol (500 mL) were added. The mixture was heated to 100 0 C and stirred for 2 hours under 5 bar of hydrogen pressure. The reaction solution was cooled to room temperature and filtered through celite to remove the catalyst. 34.2 g of NaOH and 65.0 g of benzyl chloride were successively added dropwise to the remaining filtrate.
  • the obtained filtrate was concentrated under reduced pressure to obtain 98.0 g of the targeted compound (R)-3-(benzyloxy)-4-chlorobutanenitrile (yield: 93 %).
  • the obtained product was subject to the subsequent hydrogenation without any further purification.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP06783728A 2005-08-25 2006-08-24 Verfahren zur herstellung einer chiralen 3-hydroxypyrrolidinverbindung und derivaten davon mit hoher optischer reinheit Withdrawn EP1926709A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20050078199 2005-08-25
PCT/KR2006/003341 WO2007024113A1 (en) 2005-08-25 2006-08-24 Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity
KR1020060080184A KR100743617B1 (ko) 2005-08-25 2006-08-24 고광학순도를 갖는 키랄 3-히드록시 피롤리딘 및 그유도체를 제조하는 방법

Publications (2)

Publication Number Publication Date
EP1926709A1 true EP1926709A1 (de) 2008-06-04
EP1926709A4 EP1926709A4 (de) 2009-06-24

Family

ID=37771815

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06783728A Withdrawn EP1926709A4 (de) 2005-08-25 2006-08-24 Verfahren zur herstellung einer chiralen 3-hydroxypyrrolidinverbindung und derivaten davon mit hoher optischer reinheit

Country Status (2)

Country Link
EP (1) EP1926709A4 (de)
WO (1) WO2007024113A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009318789B2 (en) 2008-11-24 2014-05-29 Council Of Scientific & Industrial Research A Process For The Preparation Of Optically Active N-Benzyl-3-Hydroxypyrrolidines
CN111518015A (zh) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法
CN111763228A (zh) * 2020-08-03 2020-10-13 连云港宏业化工有限公司 （3s）-4-氯-3-[（三甲基甲硅烷基）氧基]丁腈合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269258A2 (de) * 1986-10-27 1988-06-01 A.H. Robins Company, Incorporated Verfahren zur Herstellung einer Pyrrolidinolverbindung

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823187A (en) 1972-06-19 1974-07-09 Bristol Myers Co Production of l(-)-gamma-amino-alpha-hydroxybutyric acid
JPS6163652A (ja) 1984-09-04 1986-04-01 Yamanouchi Pharmaceut Co Ltd （ｓ）−（−）−１−ベンジル−３−ヒドロキシピロリジンの製造法
JP2703768B2 (ja) 1987-11-28 1998-01-26 鐘淵化学工業株式会社 光学活性３−ヒドロキシピロリジン誘導体の製造法
IE62338B1 (en) 1988-06-22 1995-01-25 Kanegafuchi Chemical Ind Process for preparing 3-pyrrolidinol
US5233053A (en) 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
JP2735326B2 (ja) 1989-12-02 1998-04-02 鐘淵化学工業株式会社 ３‐ピロリジノールの製造法
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
JPH0776209B2 (ja) 1990-04-11 1995-08-16 高砂香料工業株式会社 光学活性３―ヒドロキシピロリジン誘導体の製造方法
JPH04131093A (ja) 1990-09-19 1992-05-01 Denki Kagaku Kogyo Kk 混合物の製造法
US5237088A (en) 1992-03-25 1993-08-17 E. I. Du Pont De Nemours And Company Transfer hydrogenation of nitriles using amine donors
JP3159800B2 (ja) 1992-08-28 2001-04-23 ダイセル化学工業株式会社 光学異性体の分離法
JPH06141876A (ja) 1992-11-10 1994-05-24 Kyowa Hakko Kogyo Co Ltd 光学活性なｎ−ベンジル−３−ピロリジノールの製造法
JPH06211782A (ja) 1993-01-19 1994-08-02 Denki Kagaku Kogyo Kk アルコールとその誘導体の分離法
BE1007297A3 (nl) 1993-07-19 1995-05-09 Dsm Nv Werkwijze voor de bereiding van optisch aktieve alcoholen en esters, en alcoholen en esters toegepast en bereid in dergelijke werkwijzen.
JP3346852B2 (ja) 1993-10-26 2002-11-18 松下電工株式会社 脈拍検出装置
DE69413560T2 (de) 1993-12-28 1999-04-22 Rhone Poulenc Fibres Verfahren zur herstellung eines katalysators für die hydrierung von nitrilen in aminen und verwendung dieses katalysators in der hydrierung
EP1002871A1 (de) * 1998-11-17 2000-05-24 Eidgenössische Technische Hochschule (ETH) Zürich Verfahren zur Herstellung von optisch aktiven 3-hydroxy-pyrrolidinderivaten durch enzymatische Hydroxylierung
KR100461569B1 (ko) * 2002-05-20 2004-12-14 삼성정밀화학 주식회사 광학적으로 순수한 3-히드록시-피롤리딘의 제조방법
KR100523321B1 (ko) * 2002-12-27 2005-10-24 한국화학연구원 4-히드록시-2-피롤리디논의 제조방법
KR100572687B1 (ko) * 2004-05-25 2006-04-24 주식회사 알에스텍 광학적으로 순수한 4-하이드록시-2-옥소-1-피롤리딘아세트아미드의 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269258A2 (de) * 1986-10-27 1988-06-01 A.H. Robins Company, Incorporated Verfahren zur Herstellung einer Pyrrolidinolverbindung

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARRIS B D ET AL: "SYNTHESIS OF 3S-PYRROLIDINOL FROM L-GLUTAMIC ACID" SYNTHETIC COMMUNICATIONS, TAYLOR & FRANCIS GROUP, PHILADELPHIA, PA, vol. 16, no. 14, 1 January 1986 (1986-01-01), pages 1815-1822, XP008075594 ISSN: 0039-7911 *
MURAHASHI S-I ET AL: "Synthesis of (R)- and (S)-3-(tert-butyldimethylsilyloxy)-1-pyrro line N-oxides -- chiral nitrones for synthesis of biologically active pyrrolidine derivative, Geissman-Waiss lactone" TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 39, no. 18, 30 April 1998 (1998-04-30), pages 2765-2766, XP004113343 ISSN: 0040-4039 *
PELLEGATA R ET AL: "AN IMPROVED SYNTHESIS OF GAMMA-, DELTA-, AND EPSILON-LACTAMS" SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, 1 August 1978 (1978-08-01), pages 614-616, XP000673066 ISSN: 0039-7881 *
See also references of WO2007024113A1 *

Also Published As

Publication number Publication date
WO2007024113A1 (en) 2007-03-01
EP1926709A4 (de) 2009-06-24

Similar Documents

Publication Publication Date Title
EP2049464B1 (de) Herstellung von 3-[(1r,2r)-3-(dimethylamino)-1ethyl-2-methylpropyl]phenol
JP2023002679A (ja) チトクロームｐ４５０モノオキシゲナーゼの阻害剤およびそれに関わる中間体
EP1713801B1 (de) Verfahren zur herstellung von 1-(2s,3s)-2-benzhydril-n-(5-tert.-butyl-2-methoxybenzyl)chinuklidin-3-amin
EA019431B1 (ru) Способ и промежуточные соединения для получения ингибиторов интегразы
EP2611776B1 (de) Herstellungsverfahren für eine intermediatverbindung zur synthese eines medikaments
EP0452143B1 (de) Herstellungsverfahren für optisch aktive 3-Hydroxypyrrolidinderivate
JP2818763B2 (ja) Ｎ−（ヒドロキシ）アラルキルフェニルエタノールアミン類のｏ−アルキル化された化合物
EP1926709A1 (de) Verfahren zur herstellung einer chiralen 3-hydroxypyrrolidinverbindung und derivaten davon mit hoher optischer reinheit
TW200831478A (en) Chromane derivatives, synthesis thereof, and intermediates thereto
KR100743617B1 (ko) 고광학순도를 갖는 키랄 3-히드록시 피롤리딘 및 그유도체를 제조하는 방법
KR100714197B1 (ko) 보글리보스의 제조방법
EP3746425B1 (de) Verfahren zur herstellung von (6s,15s)-3,8,13,18-tetraazaicosan-6,15-diol
US5380849A (en) Process for optically pure decahydroisoqiunolines
JP4057088B2 (ja) ピロリジン誘導体の製造方法
US20040236118A1 (en) Pyrrolidine derivatives and method of synthesizing these
JP4956614B2 (ja) ３−アミノ−５−フルオロ−４−ジアルコキシペンタン酸エステルを製造する新規な方法
JP4260941B2 (ja) アゼチジン−３−オール
JP2012116775A (ja) エクチナサイジンの製造方法
JP5561967B2 (ja) グルコース化合物及びそれらの製造方法並びにダビジインの製造方法
JP4187822B2 (ja) 光学活性４−ヒドロキシ−２−ピロリドンの製造方法
JP2703048B2 (ja) プロリン誘導体の製法
KR100896087B1 (ko) 광학적으로 순수한 2-메틸피롤리딘 및 그 염의 제조방법
KR100532042B1 (ko) 질소가 이중치환된 7-아미노-3,5-디하이드록시 헵탄산유도체의 제조방법
JP2002212155A (ja) 光学活性アスパラギンエステル誘導体、光学活性３−アミノピロリジン−２，５−ジオン誘導体および光学活性３−アミノピロリジン誘導体の製造方法
JPH03176463A (ja) ピロリジノール誘導体およびその製法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090525

17Q First examination report despatched

Effective date: 20090916

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101208